Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.17B | 1.10B | 1.25B | 773.69M | 594.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.17B | 1.10B | 1.25B | 773.69M | 594.19M |
| Cost of Revenue | 211.12M | 267.72M | 200.15M | 142.95M | 71.04M |
| Gross Profit | 956.05M | 829.31M | 1.05B | 630.74M | 523.15M |
| SG&A Expenses | 322.55M | 325.37M | 322.08M | 323.31M | 239.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 898.54M | 965.32M | 881.04M | 789.89M | 576.11M |
| Operating Income | 268.64M | 131.72M | 367.98M | -16.20M | 18.08M |
| Income Before Tax | 221.65M | 161.14M | 238.97M | -35.36M | -2.37M |
| Income Tax Expenses | 15.66M | -25.28M | -12.12M | 30.92M | 15.88M |
| Earnings from Continuing Operations | 205.99M | 186.42M | 251.08M | -66.28M | -18.25M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 205.99M | 186.42M | 251.08M | -66.28M | -18.25M |
| EBIT | 268.64M | 131.72M | 367.98M | -16.20M | 18.08M |
| EBITDA | 282.19M | 145.22M | 381.79M | -2.26M | 32.48M |
| EPS Basic | 1.55 | 1.41 | 1.91 | -0.51 | -0.14 |
| Normalized Basic EPS | 1.04 | 0.58 | 1.32 | -0.16 | -0.01 |
| EPS Diluted | 1.51 | 1.37 | 1.84 | -0.51 | -0.14 |
| Normalized Diluted EPS | 1.00 | 0.56 | 1.27 | -0.16 | -0.01 |
| Average Basic Shares Outstanding | 132.89M | 132.23M | 131.45M | 130.63M | 129.68M |
| Average Diluted Shares Outstanding | 138.23M | 136.28M | 137.35M | 130.63M | 129.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |